Pharmaceutical Business review

UCB sells anti-haemorrhagic drug to Eumedica

Somatostatine-UCB is indicated for the treatment of acute upper gastrointestinal bleeding resulting from gastric and duodenal ulcers and other.

UCB receives a cash consideration of an industry average sales multiple for established products. Further details of the agreement are not disclosed.

The distribution of Somatostatine-UCB will be organized from the new worldwide logistical center of the group in Manage, Belgium.